摘要
目的探讨血栓心脉宁联合美托洛尔对冠心病经皮冠状动脉介入治疗(PCI)术后患者心肌酶(CK-MB)和肌钙蛋白(cTn)的影响。方法选取舟山医院2020年3月至2021年3月接受PCI治疗的冠心病患者104例为观察对象,采用随机数字表法分为观察组和对照组,每组52例。对照组给予美托洛尔口服治疗,25 mg/次,3次/d;观察组在对照组基础上给予血栓心脉宁片治疗,2片/次,3次/d;两组均连续治疗1个月。比较两组患者的临床疗效、治疗前后血管内皮功能、血清炎症因子等水平变化及不良反应发生率。结果观察组治疗总有效率[86.54%(45/52)]高于对照组[67.31%(35/52)](χ^(2)=4.99,P<0.05);治疗后,观察组一氧化氮(NO)[(67.23±9.52)μmol/L]高于对照组[(60.49±9.71)μmol/L],内皮素(ET)[(53.12±7.28)ng/L]低于对照组[(61.25±8.36)ng/L](t=3.57、5.28,均P<0.001);观察组肿瘤坏死因子α(TNF-α)[(39.51±6.37)μg/L]、C反应蛋白(CRP)[(4.13±1.02)mg/L]、白细胞介素6(IL-6)[(19.43±2.57)μg/L]均低于对照组[(51.37±7.28)μg/L、(5.62±1.15)mg/L、(26.16±3.19)μg/L](t=8.84、6.99、11.84,均P<0.001);观察组心肌酶(CK-MB)[(30.18±5.89)U/L]、心肌肌钙蛋白(cTn)[(7.32±1.12)ng/L]均低于对照组[(41.74±6.76)U/L、(9.63±1.45)ng/L](t=9.29、9.09,均P<0.001)。两组治疗期间均未发生严重不良反应。结论PCI术后冠心病患者采用血栓心脉宁联合美托洛尔治疗效果显著,能明显降低患者炎症反应及心肌酶水平,改善血管内皮功能。
Objective To investigate the effects of Xueshuan Xinmaining tablet combined with metoprolol on creatine kinase-MB and troponin in patients with coronary heart disease after percutaneous coronary intervention.Methods A total of 104 patients with coronary heart disease who received percutaneous coronary intervention in Zhoushan Hospital from March 2020 to March 2021 were included in this study.They were randomly divided into observation and control groups(n=52/group).The control group was give metoprolol(oral,25 mg once,3 times/day).The observation group was given Xueshuan Xinmaining tablet(2 tablets once,3 times per day)based on medication given in the control group.Two groups were treated for 1 month.Clinical efficacy,changes in vascular endothelial function and serum inflammatory factors post-treatment relative to those before treatment,and the incidence of adverse reactions were compared between the two groups.Results Total response rate in the observation group was significantly higher than that in the control group[86.54%(45/52)vs.67.31%(35/52),χ^(2)=4.99,P<0.05].After treatment,nitric oxide in the observation group was significantly higher than that in the control group[(67.23±9.52)μmol/L vs.(60.49±9.71)μmol/L,t=3.57,P<0.001].Endothelin in the observation group was significantly lower than that in the control group[(53.12±7.28)ng/L vs.(61.25±8.36)ng/L,t=5.28,P<0.001].Tumor necrosis factorα,C-reactive protein and interleukin-6 in the observation group were(39.51±6.37)μg/L,(4.13±1.02)mg/L,and(19.43±2.57)μg/L,respectively,which were significantly lower than(51.37±7.28)μg/L,(5.62±1.15)mg/L,(26.16±3.19)μg/L in the control group(t=8.84,6.99,11.84,all P<0.05).Creatine kinase-MB and troponin in the observation group were(30.18±5.89)U/L and(7.32±1.12)ng/L,respectively,which were significantly lower than(41.74±6.76)U/L and(9.63±1.45)ng/L in the control group,respectively(t=9.29,9.09,both P<0.05).No serious adverse reactions occurred during the treatment period in each group.Conclusion Xueshuan Xi
作者
金倩倩
孙思美
吴飞跃
房兆飞
Jin Qianqian;Sun Simei;Wu Feiyue;Fang Zhaofei(Department of Pharmacy,Zhoushan Hospital,Zhoushan 316000,Zhejiang Province,China;Department of Internal Medicine-Cardiovascular,Zhoushan Hospital,Zhoushan 316000,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2022年第11期1611-1615,共5页
Chinese Journal of Primary Medicine and Pharmacy
